Drug Trial Radar · NCT02390089
Cough According to Stimulus Type in PD
Last checked: Nov 19, 2026Latest source record: Feb 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
Apr 2015
Primary completion
Feb 10, 2017
Study completion Feb 13, 2019
Sponsor
- Lead sponsor
- University of FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- First posted
- Mar 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Aspiration pneumonia (APn) occurs at a higher rate in patients with Parkinson's disease (PD) versus healthy adults. This is of particular public health concern given that death secondary to aspiration pneumonia and lung infection is a leading cause of death in persons with PD. Swallowing and cough function are affected in PD, putting people with PD at significant risk for uncompensated aspiration (aspiration without adequate cough response). One challenge in the management of airway protective deficits related to PD is the chronic and progressive nature of the disease, where swallowing dysfunction appears subtly in the form of microaspiration, reducing the perceived urgency of the swallowing disorder by both clinicians and patients. The long-term goal of this research is to advance the management of airway protection deficits in patients with neurodegenerative disease in order to decrease morbidity and mortality due to aspiration related lung infection. The objective here is to further specify deficits leading to uncompensated airway compromise in PD in order to advance the clinical management of these patients, leading to an immediate positive impact.
Conditions
- Parkinson's Disease
Interventions
Capsaicin vaporDrug
Single-breath and continuous inhalation paradigm to induce cough.
fogOther
Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
Videofluoroscopic swallow evaluationRadiation
Fluoroscopic evaluation of oropharyngeal swallowing function.
NebulizerDevice
A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urge-to-cough sensitivityTime frame: 30 minute
- Positive/negative cough responseTime frame: 10 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Florida Center for Movement Disorders and Neurorestoration
Gainesville, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.